About: Serum anti-NMDA-receptor antibodies and cognitive function after ischemic stroke (PROSCIS-B)

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Serum anti-NMDA-receptor antibodies and cognitive function after ischemic stroke (PROSCIS-B) Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Serum anti-NMDA-receptor antibodies and cognitive function after ischemic stroke (PROSCIS-B)
Creator	Endres, Matthias Prüss, Harald Broersen, Leonie Gebert, Pimrapat Heuschmann, Peter »more»
source	MedRxiv
abstract	Objective: We aimed to investigate whether serum anti-N-Methyl-D-Aspartate-receptor GluN1 antibodies (NMDAR1-abs) are associated with worse cognitive function over three years after first ischemic stroke. Methods: Data were used from the PROSpective Cohort with Incident Stroke-Berlin (PROSCIS-B;NCT01363856). NMDAR1-abs (IgM/IgA/IgG) were measured with cell-based assays from serum obtained within seven days after first-ever stroke. Seropositivity was defined as titers >1:10, low titers as <1:100 and high titers as >1:100. We assessed cognitive status annually up to three years after stroke with the Telephone Interview for Cognitive Status - modified (TICS-m) and used crude and adjusted linear mixed models to estimate the impact of NMDAR1-abs exposure on TICS-m over time. Results: Data on NMDAR1-abs (median day of sampling=4[IQR=2-5]) were available in 583 of 621 PROSCIS-B patients (39% female; median NIHSS=2[IQR=1-4]; median MMSE=28[IQR:26-30]; median mRS=2[IQR=1-3]) of whom 76(13%) were seropositive (IgM:n=48/IgA:n=43/IgG:n=2). TICS-m over time was not different in NMDAR1-abs seropositive compared to seronegative patients (Crude beta=0.38[95%CI=-1.00 to 1.76]; adjusted beta Model3=0.30[95%CI=-1.14 to 1.73]). In subgroups, TICS-m over time was not different in patients with low titers (Crude beta=1.53[95%CI=-0.06 to 3.11]; adjusted beta Model3=1.42[95%CI= 0.23 to 3.08]), however, in patients with high titers TICS-m was lower in the crude model (Crude beta= 2.54[95%CI=-4.99 to -0.08]), with a similar effect size after confounder adjustment (adjusted beta Model3=-2.30[95%CI=-4.82 to 0.21]). All groups were compared to seronegative patients, respectively. Conclusion: Overall NMDAR1-abs seropositivity was not associated with cognitive function over time after first-ever mild-to-moderate ischemic stroke. Our data suggest that high titers associate with impaired cognitive function after stroke, warranting larger studies.
has issue date	2020-04-18(xsd:dateTime)
bibo:doi	10.1101/2020.04.15.20066324
has license	medrxiv
sha1sum (hex)	9f5f873c7dd4ca4255e00db53dd43d1bd96b339c
schema:url	https://doi.org/10.1101/2020.04.15.20066324
resource representing a document's title	Serum anti-NMDA-receptor antibodies and cognitive function after ischemic stroke (PROSCIS-B)
resource representing a document's body	covid:9f5f873c7dd4ca4255e00db53dd43d1bd96b339c#body_text
is schema:about of	named entity 'abs' named entity 'antibodies' named entity 'ischemic stroke' named entity 'antibodies' named entity 'IgA' »more»

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software